Bookmark and Share
BioAssay: AID 623944

ML300 Competition in Radioligand Binding assays (Ricerca)

The purpose of this assay was to follow up on the confirmatory and dose-response testing of the validated lead SAR series to characterize the candidate 3CLpro probe compound ML300 for ancillary pharmacology in counter screens via the commercial Ricerca Biosciences, LLC radioligand binding assay panels targeting G-protein coupled receptors, neurotransmitter transporters and ion channels. ..more
_
   
 Tested Compounds
 Tested Compounds
All(1)
 
 
Inactive(1)
 
 
 Tested Substances
 Tested Substances
All(1)
 
 
Inactive(1)
 
 
 Related BioAssays
 Related BioAssays
AID: 623944
Data Source: Vanderbilt Specialized Chemistry Center (ML300_Ricerca_Binding)
Depositor Category: NIH Molecular Libraries Probe Production Network
Deposit Date: 2012-03-29
Hold-until Date: 2013-03-29
Modify Date: 2013-03-29

Data Table ( Complete ):           View All Data
Tested Compound:
Related Experiments
Show more
AIDNameTypeComment
1859Summary of probe development efforts to identify inhibitors of the SARS coronavirus 3C-like Protease (3CLPro)Summarydepositor-specified cross reference: Summary of probe development efforts to identify inhibitors of the SARS coronavirus 3C-like Protease
1706QFRET-based primary biochemical high throughput screening assay to identify inhibitors of the SARS coronavirus 3C-like Protease (3CLPro)Screeningsame project related to Summary assay
1890QFRET-based dose response biochemical high throughput screening assay to identify inhibitors of the SARS coronavirus 3C-like Protease (3CLPro)Confirmatorysame project related to Summary assay
1944Luminescence-based counterscreen for inhibitors of the SARS coronavirus 3C-like Protease (3CLPro): dose response biochemical high throughput screening assay to identify inhibitors of the papain-like protease (PLpro)Confirmatorysame project related to Summary assay
435015Late stage counterscreen results from the probe development effort to identify inhibitors of the SARS coronavirus 3C-like Protease (3CLPro); luminescence-based cell-based assay to identify cytotoxic compounds in Vero E6 cellsScreeningsame project related to Summary assay
488877Late stage assay provider counterscreen results from the probe development effort to identify inhibitors of the SARS coronavirus 3C-like Protease (3CLPro): luminescence-based dose-response cell-based assay for restoration of viability of SARS-CoV-infected Vero cellsConfirmatorysame project related to Summary assay
488958Late stage assay provider results from the probe development effort to identify inhibitors of the SARS coronavirus 3C-like Protease (3CLPro): fluorescence-based biochemical dose-response assay for inhibitors of 3CLProConfirmatorysame project related to Summary assay
488967Late stage assay provider results from the probe development effort to identify inhibitors of the SARS coronavirus 3C-like Protease (3CLPro): fluorescence-based biochemical assay for inhibitors of 3CLProOthersame project related to Summary assay
488984Late stage assay provider results from the probe development effort to identify inhibitors of the SARS coronavirus 3C-like Protease (3CLPro): fluorescence-based biochemical assay for inhibitors of 3CLPro: Set 2Othersame project related to Summary assay
488999Late stage assay provider results from the probe development effort to identify inhibitors of the SARS coronavirus 3C-like Protease (3CLPro): fluorescence-based biochemical dose-response assay for inhibitors of 3CLPro; Set 2Confirmatorysame project related to Summary assay
493245Late stage assay provider results from the probe development effort to identify inhibitors of the SARS coronavirus 3C-like Protease (3CLPro): fluorescence-based biochemical assay for inhibitors of 3CLPro: Set 3Othersame project related to Summary assay
588771Late stage assay provider results from the probe development effort to identify inhibitors of the SARS coronavirus 3C-like Protease (3CLPro): fluorescence-based biochemical dose-response assay for inhibitors of 3CLPro; Set 3Confirmatorysame project related to Summary assay
588772Late stage assay provider results from the probe development effort to identify inhibitors of the SARS coronavirus 3C-like Protease (3CLPro): fluorescence-based biochemical assay for inhibitors of 3CLPro: Set 4Othersame project related to Summary assay
588786Late stage assay provider results from the probe development effort to identify inhibitors of the SARS coronavirus 3C-like Protease (3CLPro): fluorescence-based biochemical dose-response assay for inhibitors of 3CLPro; Set 4Confirmatorysame project related to Summary assay
602486Late stage assay provider results from the probe development effort to identify inhibitors of the SARS coronavirus 3C-like Protease (3CLPro): fluorescence-based biochemical dose-response assay for inhibitors of 3CLPro; Set 5Confirmatorysame project related to Summary assay
602487Late stage assay provider results from the probe development effort to identify inhibitors of the SARS coronavirus 3C-like Protease (3CLPro): fluorescence-based biochemical assay for inhibitors of 3CLPro: Set 5Othersame project related to Summary assay
Description:
The purpose of this assay was to follow up on the confirmatory and dose-response testing of the validated lead SAR series to characterize the candidate 3CLpro probe compound ML300 for ancillary pharmacology in counter screens via the commercial Ricerca Biosciences, LLC radioligand binding assay panels targeting G-protein coupled receptors, neurotransmitter transporters and ion channels.
Protocol
Methods employed in this study have been adapted from the scientific literature by Ricerca Biosciences, LLC to maximize reliability and reproducibility. Reference standards were run as an integral part of each assay to ensure the validity of the results obtained. Assays were performed under conditions described in an extensive "Methods" section available from Ricerca Biosciences, LLC using a 10 uM test concentration of ML300 for radioligand competition and 30uM test concentration for functional assays. Percent inhibition of target-selective radioligand binding or functional response is reported. Under the Ricerca Biosciences, LLC panel assay conditions, responses with greater than 50% inhibition are considered significant.
Comment
The ML300 probe was realtively clean of ancillary pharmacology. Only one target displayed significant inhibition in the Ricerca panel: Melatonin MT1 receptor (75% inhibition).
Result Definitions
Show more
TIDNameDescriptionHistogramTypeUnit
OutcomeThe BioAssay activity outcomeOutcome
1Adenosine_A1Percent inhibition of specific binding or activity. Integer%
2Adenosine_A2aPercent inhibition of specific binding or activity. Integer%
3Adenosine_A3 Percent inhibition of specific binding or activity. Integer%
4Adrenergic_alpha1A Percent inhibition of specific binding or activity. Integer%
5Adrenergic_alpha1B Percent inhibition of specific binding or activity. Integer%
6Adrenergic_alpha1DPercent inhibition of specific binding or activity. Integer%
7Adrenergic_alpha2APercent inhibition of specific binding or activity. Integer%
8Adrenergic_beta1Percent inhibition of specific binding or activity. Integer%
9Adrenergic_beta2Percent inhibition of specific binding or activity. Integer%
10Androgen_Testosterone_AR Percent inhibition of specific binding or activity. Integer%
11Bradykinin_B1Percent inhibition of specific binding or activity. Integer%
12Bradykinin_B2Percent inhibition of specific binding or activity. Integer%
13Calcium_Channel_Ltype_BenzothiazepinePercent inhibition of specific binding or activity. Integer%
14Calcium_Channel_Ltype_Dihydropyridine Percent inhibition of specific binding or activity. Integer%
15Calcium Channel N-Type Percent inhibition of specific binding or activity. Integer%
16Cannabinoid_CB1 Percent inhibition of specific binding or activity. Integer%
17Dopamine_D1 Percent inhibition of specific binding or activity. Integer%
18Dopamine_D2SPercent inhibition of specific binding or activity. Integer%
19Dopamine_D3Percent inhibition of specific binding or activity. Integer%
20Dopamine_D4,2 Percent inhibition of specific binding or activity. Integer%
21Endothelin_EtaPercent inhibition of specific binding or activity. Integer%
22Endothelin_ETbPercent inhibition of specific binding or activity. Integer%
23Epidermal_Growth_Factor_EGF Percent inhibition of specific binding or activity. Integer%
24Estrogen_ER_alphaPercent inhibition of specific binding or activity. Integer%
25GABA_A_Flunitrazepam_Central Percent inhibition of specific binding or activity. Integer%
26GABA_A_Muscimol_Central Percent inhibition of specific binding or activity. Integer%
27GABA_B_1APercent inhibition of specific binding or activity. Integer%
28Glucocorticoid Percent inhibition of specific binding or activity. Integer%
29Glutamate_Kainate Percent inhibition of specific binding or activity. Integer%
30Glutamate_NMDA_Agonism Percent inhibition of specific binding or activity. Integer%
31Glutamate_NMDA_Glycine Percent inhibition of specific binding or activity. Integer%
32Glutamate_NMDA_Phencyclidine Percent inhibition of specific binding or activity. Integer%
33Histamine_H1 Percent inhibition of specific binding or activity. Integer%
34Histamine_H2 Percent inhibition of specific binding or activity. Integer%
35 Histamine_H3 Percent inhibition of specific binding or activity. Integer%
36Imidazoline_I2_Central Percent inhibition of specific binding or activity. Integer%
37Interleukin_IL1 Percent inhibition of specific binding or activity. Integer%
38Leukotriene_Cysteinyl_CysLT1 Percent inhibition of specific binding or activity. Integer%
39Melatonin_MT1 Percent inhibition of specific binding or activity. Integer%
40Muscarinic_M1 Percent inhibition of specific binding or activity. Integer%
41Muscarinic_M2 Percent inhibition of specific binding or activity. Integer%
42Muscarinic_M3Percent inhibition of specific binding or activity. Integer%
43NeuropeptideY_Y1 Percent inhibition of specific binding or activity. Integer%
44NeuropeptideY_Y2 Percent inhibition of specific binding or activity. Integer%
45Nicotinic_Acetylcholine Percent inhibition of specific binding or activity. Integer%
46Nicotinic_Acetylcholine_alpha1_BungarotoxinPercent inhibition of specific binding or activity. Integer%
47Opiate_delta1_OP1_DOP Percent inhibition of specific binding or activity. Integer%
48Opiate_kappa_OP2_KOPPercent inhibition of specific binding or activity. Integer%
49Opiate_mu_OP3_MOP Percent inhibition of specific binding or activity. Integer%
50Phorbol_Ester Percent inhibition of specific binding or activity. Integer%
51Platelet_Activating_Factor_PAF Percent inhibition of specific binding or activity. Integer%
52Potassium_Channel_K_ATP Percent inhibition of specific binding or activity. Integer%
53Potassium_Channel_hERG Percent inhibition of specific binding or activity. Integer%
54Prostanoid_EP4 Percent inhibition of specific binding or activity. Integer%
55Purinergic_P2XYPercent inhibition of specific binding or activity. Integer%
56Purinergic_P2YPercent inhibition of specific binding or activity. Integer%
57Rolipram Percent inhibition of specific binding or activity. Integer%
58Serotonin_5HT1APercent inhibition of specific binding or activity. Integer%
59Serotonin_5HT2B Percent inhibition of specific binding or activity. Integer%
60Serotonin_5HT3 Percent inhibition of specific binding or activity. Integer%
61Sigma_rho1 Percent inhibition of specific binding or activity. Integer%
62Tachykinin_NK1Percent inhibition of specific binding or activity. Integer%
63Thyroid_HormonePercent inhibition of specific binding or activity. Integer%
64Transporter_Dopamine_DAT Percent inhibition of specific binding or activity. Integer%
65Transporter_GABAPercent inhibition of specific binding or activity. Integer%
66Transporter_Norepinephrine_NETPercent inhibition of specific binding or activity. Integer%
67Transporter_Serotonin_5-Hydroxytryptamine_SERT Percent inhibition of specific binding or activity. Integer%
Additional Information
Grant Number: 1-RO3-MH084162-01A1

Data Table (Concise)
Data Table ( Complete ):     View All Data
PageFrom: